Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
D000293:Adolescent; D000328:Adult; D000368:Aged; D006585:Altretamine / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012552:Schistosomiasis / Q000150:complications*; D013713:Teniposide / Q000627:therapeutic use*; D014227:Triazines / Q000627:therapeutic use*; D001745:Urinary Bladder Diseases / Q000150:complications*; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000188:drug therapy*
D014227:Triazines; D013713:Teniposide; D011034:Podophyllotoxin; D006585:Altretamine